Right Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction

A prevalent and challenging form of heart failure known as heart failure with preserved ejection fraction affects approximately 3 million people in the United States, predominantly women and individuals with conditions like hypertension, diabetes, and obesity. Researchers at the University of Wisconsin-Madison and the Morgridge Institute for Research published a study on August 24, 2026, in Circulation: Heart Failure revealing that right ventricular dysfunction serves as a critical prognostic indicator for worse patient outcomes and higher mortality rates. The study demonstrates how left-sided heart stiffening elevates pulmonary vascular pressure, causing severe turbulence and subsequent right ventricular strain, which standard broader treatments like sildenafil or levosimendan have historically failed to alleviate. By utilizing advanced long-read RNA sequencing and cardiac evaluations on 48 patients, the research team identified specific molecular disruptions, notably reduced mitochondrial function and elevated variants in the GATD3 gene linked to cellular energy metabolism. The core discovery emphasizes that patient responses vary significantly due to underlying biological differences, making broad population treatments ineffective. Pinpointing right ventricular performance and energy metabolism markers allows modern cardiology to transition toward precision medicine, matching specific disease pathways with existing targeted pharmacological interventions. Clinical professionals and researchers can utilize these findings to stratify heart failure patients into distinct biological subgroups, designing future precision clinical trials that target mitochondrial and RNA processing abnormalities to dramatically improve quality of life and decrease mortality.